FL 779
Alternative Names: FL-779Latest Information Update: 15 Feb 2024
At a glance
- Originator Canget BioTekpharma
- Class Antineoplastics; Camptothecins; Small molecules
- Mechanism of Action Apoptosis stimulants; DNA topoisomerase I inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Lymphoma
Most Recent Events
- 24 Jan 2024 FL 779 is available for licensing as of 24 Jan 2024. http://www.canget-biotek.com/business%20models.php (Canget BioTekpharma pipeline, January 2024)
- 24 Jan 2024 Preclinical trials in Lymphoma in USA (PO) prior to January 2024 (Canget BioTekpharma pipeline, January 2024)
- 28 Dec 2023 Pharmacodynamics data from preclinical studies in Lymphoma released by Canget BioTekpharma